Clinical Trials
Overview
The Penn FTD Center is dedicated to pursuing pharmaceutical trials designed to alleviate or treat some of the symptoms associated with neurodegenerative conditions. Clinical treatment trials involve the administration of an investigational drug or a placebo to eligible participants to assess how the study drug may affect thinking or behavior. Each participant’s health is monitored throughout the course of the study via routine clinical blood tests, MRIs, and ECGs to ensure that risk from the study drug is minimized. The investigational agent is provided by a pharmaceutical company, which sponsors the treatment trial. Procedures, materials, and examinations associated with the trial are provided at no cost to eligible participants. We also perform preclinical trial studies to identify the best methods for monitoring responses to a treatment. This may include neuropsychological measures, MRI studies, blood tests or lumbar puncture.
Current Clinical Trials
The Penn FTD Center is currently participating in the following clinical trials:
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS- 241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer’s Disease. Study consists of 9 weekly infusion visits, two Lumbar Punctures and two MRI scans.
- A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (TauRX)-- This study is not yet open for enrollment.
